Aspirin did not provide any clinical benefits in a cohort of patients with colorectal cancer who had no history of cardiovascular disease or stroke.

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

Researchers, federal employees, and members of the public have voiced concerns about restrictions recently placed on federal health agencies.

The FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice regulations for active pharmaceutical ingredients.

Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

A growing body of research suggests that exposure to PFAS, commonly called "forever chemicals," may increase a person's risk ...

Adding pamrevlumab to chemotherapy did not improve survival in patients with previously untreated, locally advanced pancreatic cancer.

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

Policies that improve payer coverage, streamline authorization processes, and reduce cost-sharing burdens for medical equipment are urgently needed,” according to researchers.

Neoadjuvant CRT plus sintilimab yielded a higher pCR rate than neoadjuvant chemo plus sintilimab in patients with locally advanced ESCC.